KBS Research
Plano, US · Founded 2012 · Texas LLC
KBS Research is a physician-led R&D company that develops polyphenol-based formulations targeting the biological mechanisms behind digestive and metabolic conditions such as IBS, SIBO, bloating, and GERD. It validates its clinically studied products (including Atrantil and Re:flux) through structured human studies combining gastroenterology, microbiome science, and polyphenol chemistry.
Founders & leadership
ML
Michael LogsdonExecutive
CS
Charles ScottExecutive
BS
Brandi ScottExecutive
KB
Kenneth BrownNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.4M disclosed across 1 round · 2015
▶$2.4MraisedDec 2015 · 11 investors · Other Health CareRule 506(c)
▶$2.4MraisedDec 2015 · 11 investors · Other Health Care
Rule 506(c)Officers, directors & promoters on the filing
- Michael LogsdonExecutive Officer
- Charles ScottExecutive Officer
- Kenneth BrownExecutive Officer
- Brandi ScottExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.4M
- Minimum investment
- $250K
- Incorporated
- Limited Liability Company, Texas, 2012
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does KBS Research do?
- KBS Research is a physician-led R&D company that develops polyphenol-based formulations targeting the biological mechanisms behind digestive and metabolic conditions such as IBS, SIBO, bloating, and GERD. It validates its clinically studied products (including Atrantil and Re:flux) through structured human studies combining gastroenterology, microbiome science, and polyphenol chemistry.
- How much funding has KBS Research raised?
- KBS Research has disclosed $2.4M raised across 1 round.
- Where is KBS Research headquartered?
- KBS Research is headquartered in Plano, US.